NCT03145181 - Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

302

Participants

Timeline

Start Date

May 16, 2017

Primary Completion Date

November 9, 2021

Study Completion Date

May 28, 2027

Conditions

Hematological Malignancies

Interventions

DRUG

Teclistamab (IV)

Participants will receive IV infusion of Teclistamab.

DRUG

Teclistamab(SC)

Participants will receive SC injection of Teclistamab.

Trial Locations (13)

10029

Icahn School of Medicine at Mount Sinai Program for the Protection of Human Subjects, New York

19104

University of Pennsylvania, Philadelphia

28204

Levine Cancer Institute, Charlotte

31008

Clinica Univ. de Navarra, Pamplona

37007

Hosp Clinico Univ de Salamanca, Salamanca

37044

CHRU Tours Hopital Bretonneau, Tours

69495

Centre hospitalier Lyon-Sud, Pierre-Bénite

80218

Colorado Blood Cancer Institute, Denver

91010

City of Hope, Duarte

1081 HV

VU Medisch Centrum, Amsterdam

08916

Hosp. Univ. Germans Trias I Pujol, Badalona

08036

Hosp Clinic de Barcelona, Barcelona

SE-141 86

Haematology Centre, R 51, Stockholm

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY